Class information for: |
Basic class information |
Class id | #P | Avg. number of references |
Database coverage of references |
---|---|---|---|
22094 | 393 | 40.9 | 76% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
0 | 4 | BIOCHEMISTRY & MOLECULAR BIOLOGY//CELL BIOLOGY//ONCOLOGY | 4064930 |
210 | 3 | IMMUNOLOGY//JOURNAL OF INTERFERON RESEARCH//NK CELLS | 51916 |
1202 | 2 | JOURNAL OF INTERFERON RESEARCH//INTERFERON//JOURNAL OF INTERFERON AND CYTOKINE RESEARCH | 9220 |
22094 | 1 | SECT STUDIES HOST IMMUNE PONSE//GENE IMMUNE MED//CANC BIOL 173 | 393 |
Terms with highest relevance score |
rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|---|
1 | SECT STUDIES HOST IMMUNE PONSE | address | 171458 | 2% | 28% | 8 |
2 | GENE IMMUNE MED | address | 149412 | 1% | 38% | 5 |
3 | CANC BIOL 173 | address | 131271 | 2% | 24% | 7 |
4 | ADENOVIRUS ENCODING IFN BETA | authKW | 77697 | 0% | 100% | 1 |
5 | ANTI ENDOTHELIAL TREATMENT | authKW | 77697 | 0% | 100% | 1 |
6 | ANTI GLUCOCORTICOID INDUCED TNF RECEPTOR ANTIBODY | authKW | 77697 | 0% | 100% | 1 |
7 | BFGF IFN BETA UVB RADIATION | authKW | 77697 | 0% | 100% | 1 |
8 | CD2 DEPENDENT ACTIVATION | authKW | 77697 | 0% | 100% | 1 |
9 | CD3 DEPENDENT ACTIVATION | authKW | 77697 | 0% | 100% | 1 |
10 | CLIN INVEST BIOTHER IE CIC BT 511 | address | 77697 | 0% | 100% | 1 |
Web of Science journal categories |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | Oncology | 3061 | 46% | 0% | 180 |
2 | Immunology | 812 | 23% | 0% | 90 |
3 | Medicine, Research & Experimental | 587 | 15% | 0% | 60 |
4 | Virology | 178 | 6% | 0% | 22 |
5 | Biotechnology & Applied Microbiology | 162 | 10% | 0% | 39 |
6 | Cell Biology | 131 | 11% | 0% | 44 |
7 | Genetics & Heredity | 122 | 9% | 0% | 34 |
8 | Pathology | 56 | 4% | 0% | 16 |
9 | Biochemistry & Molecular Biology | 51 | 14% | 0% | 55 |
10 | Hematology | 6 | 2% | 0% | 8 |
Address terms |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | SECT STUDIES HOST IMMUNE PONSE | 171458 | 2% | 28% | 8 |
2 | GENE IMMUNE MED | 149412 | 1% | 38% | 5 |
3 | CANC BIOL 173 | 131271 | 2% | 24% | 7 |
4 | CLIN INVEST BIOTHER IE CIC BT 511 | 77697 | 0% | 100% | 1 |
5 | HLTH PROMOT HUMAN BEHAVIOUR | 77697 | 0% | 100% | 1 |
6 | INNOVAT CANC THER Y CENTURY 21COE PROGR | 77697 | 0% | 100% | 1 |
7 | MD ANDERSON CANC CELL BIOLBOX 173 | 77697 | 0% | 100% | 1 |
8 | SKIN MELANOMA UNIT | 77697 | 0% | 100% | 1 |
9 | UNITEE ASSOCIEE VIROL IMMUNOL EXPT | 77697 | 0% | 100% | 1 |
10 | UROL 110 | 77697 | 0% | 100% | 1 |
Journals |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | JOURNAL OF INTERFERON AND CYTOKINE RESEARCH | 12462 | 5% | 1% | 19 |
2 | JOURNAL OF INTERFERON RESEARCH | 5111 | 2% | 1% | 8 |
3 | CANCER GENE THERAPY | 4785 | 3% | 1% | 11 |
4 | INTERNATIONAL JOURNAL OF CANCER | 3683 | 8% | 0% | 31 |
5 | JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS | 2886 | 2% | 1% | 7 |
6 | CLINICAL CANCER RESEARCH | 1676 | 5% | 0% | 18 |
7 | GENE THERAPY | 1258 | 2% | 0% | 8 |
8 | CANCER RESEARCH | 1216 | 6% | 0% | 25 |
9 | CLINICAL & EXPERIMENTAL METASTASIS | 965 | 1% | 0% | 5 |
10 | CYTOKINE & GROWTH FACTOR REVIEWS | 868 | 1% | 0% | 3 |
Author Key Words |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
---|---|---|---|---|
1 | GRESSER, I , (2007) THE ANTITUMOR EFFECTS OF INTERFERON: A PERSONAL HISTORY.BIOCHIMIE. VOL. 89. ISSUE 6-7. P. 723-728 | 24 | 65% | 24 |
2 | BELARDELLI, F , FERRANTINI, M , PROIETTI, E , KIRKWOOD, JM , (2002) INTERFERON-ALPHA IN TUMOR IMMUNITY AND IMMUNOTHERAPY.CYTOKINE & GROWTH FACTOR REVIEWS. VOL. 13. ISSUE 2. P. 119 -134 | 35 | 38% | 204 |
3 | GRESSER, I , BELARDELLI, F , (2002) ENDOGENOUS TYPE I INTERFERONS AS A DEFENSE AGAINST TUMORS.CYTOKINE & GROWTH FACTOR REVIEWS. VOL. 13. ISSUE 2. P. 111-118 | 20 | 54% | 61 |
4 | LU, WX , FIDLER, IJ , DONG, ZY , (1999) ERADICATION OF PRIMARY MURINE FIBROSARCOMAS AND INDUCTION OF SYSTEMIC IMMUNITY BY ADENOVIRUS-MEDIATED INTERFERON BETA GENE THERAPY.CANCER RESEARCH. VOL. 59. ISSUE 20. P. 5202-5208 | 23 | 51% | 31 |
5 | FERRANTINI, M , BELARDELLI, F , (2000) GENE THERAPY OF CANCER WITH INTERFERON: LESSONS FROM TUMOR MODELS AND PERSPECTIVES FOR CLINICAL APPLICATIONS.SEMINARS IN CANCER BIOLOGY. VOL. 10. ISSUE 2. P. 145 -157 | 32 | 34% | 37 |
6 | QIN, XQ , BECKHAM, C , BROWN, JL , LUKASHEV, M , BARSOUM, J , (2001) HUMAN AND MOUSE IFN-BETA GENE THERAPY EXHIBITS DIFFERENT ANTI-TUMOR MECHANISMS IN MOUSE MODELS.MOLECULAR THERAPY. VOL. 4. ISSUE 4. P. 356-364 | 19 | 56% | 31 |
7 | ZHANG, FH , LEE, J , WANG, DR , DONG, ZY , (2006) DIFFERENTIAL GROWTH OF IFN-BETA-ENGINEERED TUMOR CELLS IN NUDE AND IFN RECEPTOR-NULL MICE.JOURNAL OF INTERFERON AND CYTOKINE RESEARCH. VOL. 26. ISSUE 2. P. 108-118 | 20 | 48% | 0 |
8 | OLSON, MV , LEE, J , ZHANG, F , WANG, A , DONG, Z , (2006) INDUCIBLE NITRIC OXIDE SYNTHASE ACTIVITY IS ESSENTIAL FOR INHIBITION OF PROSTATIC TUMOR GROWTH BY INTERFERON-BETA GENE THERAPY.CANCER GENE THERAPY. VOL. 13. ISSUE 7. P. 676 -685 | 21 | 43% | 15 |
9 | SANTODONATO, L , FERRANTINI, M , PALOMBO, F , AURISICCHIO, L , DELMASTRO, P , LA MONICA, N , DI MARCO, S , CILIBERTO, G , DU, MX , TAYLOR, MW , ET AL (2001) ANTITUMOR ACTIVITY OF RECOMBINANT ADENOVIRAL VECTORS EXPRESSING MURINE IFN-ALPHA IN MICE INJECTED WITH METASTATIC IFN-RESISTANT TUMOR CELLS.CANCER GENE THERAPY. VOL. 8. ISSUE 1. P. 63-72 | 22 | 43% | 18 |
10 | INDRACCOLO, S , (2010) INTERFERON-ALPHA AS ANGIOGENESIS INHIBITOR: LEARNING FROM TUMOR MODELS.AUTOIMMUNITY. VOL. 43. ISSUE 3. P. 244-247 | 14 | 50% | 20 |
Classes with closest relation at Level 1 |